NCT06995287View on ClinicalTrials.gov

Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

222

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

September 1, 2027

Study Completion Date

January 1, 2028

Conditions
Primary DysmenorrheaChronic Pelvic Pain
Interventions
DRUG

Xeomin

One injection will be performed via hysteroscopy under local anesthesia.

DRUG

Placebo

One injection will be performed via hysteroscopy under local anesthesia.

Trial Locations (8)

Unknown

Clinique axium / Centre resilience, Aix-en-Provence

CHU Angers, Angers

CHU Brest, Brest

CHU Lille, Lille

Hôpital de la Croix-Rousse, Lyon

CHU Nantes, Nantes

Clinique Brétéché, Nantes

CHU Rennes, Rennes

Sponsors

Collaborators (1)

Merz Pharmaceuticals GmbH
All Listed Sponsors
collaborator

Merz Pharmaceuticals GmbH

INDUSTRY

collaborator

Ministry of Health, France

OTHER_GOV

lead

Nantes University Hospital

OTHER

NCT06995287 - Evaluation of the Analgesic Effect of Intramyometrial Botulinum Toxin Injection Via Hysteroscopy in Severe Primary Dysmenorrhea | Biotech Hunter | Biotech Hunter